Patents by Inventor David J. Drutz
David J. Drutz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7432252Abstract: The present invention provides a method of stimulating cervical and vaginal secretions in a mammal by treatment with P2Y2 and/or P2Y4 purinergic receptor agonists. Treatment of vaginal dryness associated with menopause, chemotherapy, and various disease states as well as the treatment of vulvar pain is discussed. Suitable agonists such as UTP, CTP, ATP, dinucleotides and analogs thereof are disclosed.Type: GrantFiled: March 20, 2000Date of Patent: October 7, 2008Assignee: Inspire Pharmaceuticals, Inc.Inventors: William Pendergast, Sammy Ray Shaver, David J. Drutz, Janet L. Rideout, Benjamin R. Yerxa
-
Publication number: 20080214490Abstract: The present invention provides a method of stimulating cervical and vaginal secretions in a mammal by treatment with P2Y2 and/or P2Y4 purinergic receptor agonists. Treatment of vaginal dryness associated with menopause, chemotherapy, and various disease states as well as the treatment of vulvar pain is discussed. Suitable agonists such as UTP, CTP, ATP, dinucleotides and analogs thereof are disclosed.Type: ApplicationFiled: March 6, 2008Publication date: September 4, 2008Applicant: Inspire Pharmaceuticals, Inc.Inventors: William Pendergast, Sammy Ray Shaver, David J. Drutz, Janet L. Rideout, Benjamin R. Yerxa
-
Patent number: 6673779Abstract: The present invention is directed to a method of stimulating ciliary beat frequency to promote mucociliary or cough clearance of retained mucus secretions from the lungs, sinuses, upper airways, ears, eyes, genito-urinary tract, spermatozoa, ovaries, fallopian tubes, neutrophils, and macrophages of a patient. The method comprises administering uridine triphosphates, adenosine triphosphates, cytidine triphosphates, or dinucleoside tetraphosphates and the derivatives thereof to an affected body of a patient, to treat dysfunction of the mucociliary clearance system as a result of impaired ciliary movement in the patient.Type: GrantFiled: June 5, 2002Date of Patent: January 6, 2004Assignees: Inspire Pharmaceuticals, Inc., The University of North Carolina at Chapel HillInventors: Karla M. Jacobus, Benjamin R. Yerxa, William Pendergast, Richard C. Boucher, Jr., Janet L. Rideout, David J. Drutz, Michael K. James, Monroe Jackson Stutts, Cara Geary, Eduardo R. Lazarowski
-
Publication number: 20030036527Abstract: The present invention is directed to a method of stimulating ciliary beat frequency to promote mucociliary or cough clearance of retained mucus secretions from the lungs, sinuses, upper airways, ears, eyes, genito-urinary tract, spermatozoa, ovaries, fallopian tubes, neutrophils, and macrophages of a patient. The method comprises administering uridine triphosphates, adenosine triphosphates, cytidine triphosphates, or dinucleoside tetraphosphates and the derivatives thereof to an affected body of a patient, to treat dysfunction of the mucociliary clearance system as a result of impaired ciliary movement in the patient.Type: ApplicationFiled: June 5, 2002Publication date: February 20, 2003Inventors: Karla M. Jacobus, Benjamin R. Yerxa, William Pendergast, Richard C. Boucher, Janet L. Rideout, David J. Drutz, Michael K. James, Monroe Jackson Stutts, Cara Geary, Eduardo R. Lazarowski
-
Patent number: 6462028Abstract: The present invention provides a method of stimulating cervical and vaginal secretions in a mammal by treatment with P2Y2 and/or P2Y4 purinergic receptor agonists. Treatment of vaginal dryness associated with menopause, chemotherapy, and various disease states as well as the treatment of vulvar pain is discussed. Suitable agonists such as UTP, CTP, ATP, dinucleotides and analogs thereof are disclosed.Type: GrantFiled: November 25, 1998Date of Patent: October 8, 2002Assignee: Inspire Pharmaceuticals, Inc.Inventors: William Pendergast, Sammy R. Shaver, David J. Drutz, Janet L. Rideout, Benjamin R. Yerxa
-
Patent number: 6423694Abstract: A method of promoting drainage of congested middle ear fluid in a subject in need of such treatment is disclosed. The method comprises administering to the middle ear of the subject a uridine triphosphate such as uridine 5′-triphosphate (UTP), an analog of UTP, or any other analog, in an amount effective to promote drainage of congested middle ear fluid by hydrating mucous secretions in the middle ear or by stimulating ciliary beat frequency in the middle ear or eustachian tube. The method is useful for treating patients afflicted with otitis media and other middle ear diseases, otitis externa, and inner ear diseases including Ménière's Disease. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the same would include any liquid suspension (including nasal drops or spray), oral, inhaled by nebulization, topical, injected or suppository form.Type: GrantFiled: February 21, 1996Date of Patent: July 23, 2002Assignee: Inspire Pharmaceuticals, Inc.Inventors: David J. Drutz, Janet L. Rideout, Karla M. Jacobus
-
Patent number: 6420347Abstract: A method of stimulating ciliary beat frequency in a subject in need of such treatment is disclosed. The method comprises administering to the airways, ears, eyes, or genito-urinary tract of the subject a triphosphate nucleotide such as uridine 5′-triphosphate (UTP), an analog of UTP, or any other analog, in an amount effective to stimulate ciliary beat frequency. This method is useful for treating patients afflicted with ciliary dyskinesia, Kartagener's syndrome, or any other disease involving dysfunction of ciliary movement, such as male infertility caused by impairment of propulsion of the spermatozoa or immune deficiency caused by impairment of ciliary movement in neutrophils or macrophages. Pharmaceutical formulations and methods of making the same are also disclosed.Type: GrantFiled: July 17, 1998Date of Patent: July 16, 2002Assignees: Inspire Pharmaceuticals, Inc., The University of North Carolina at Chapel HillInventors: Karla M. Jacobus, Benjamin R. Yerxa, William Pendergast, Richard C. Boucher, Jr., Janet L. Rideout, David J. Drutz, Michael K. James, Monroe Jackson Stutts, Cary Geary, Edwardo R. Lazarowski
-
Patent number: 6372249Abstract: The use of liposomal formulations, particularly formulations of positively charged and neutral lipids facilitates cellular uptake of SDI molecules. The transcription and/or expression of SDI-1-encoding nucleic acid molecules is facilitated by constructs that contain intervening untranslated regions.Type: GrantFiled: October 24, 1994Date of Patent: April 16, 2002Assignee: Baylor College of MedicineInventors: James R. Smith, David J. Drutz, Deborah R. Wilson, Louis A. Zumstein
-
Publication number: 20020013289Abstract: The present invention provides a method of stimulating cervical and vaginal secretions in a mammal by treatment with P2Y2 and/or P2Y4 purinergic receptor agonists. Treatment of vaginal dryness associated with menopause, chemotherapy, and various disease states as well as the treatment of vulvar pain is discussed. Suitable agonists such as UTP, CTP, ATP, dinucleotides and analogs thereof are disclosed.Type: ApplicationFiled: November 25, 1998Publication date: January 31, 2002Inventors: WILLIAM PENDERGAST, SAMMY R. SHAVER, DAVID J. DRUTZ, JANET L. RIDEOUT
-
Patent number: 5968913Abstract: Novel pharmaceutical compositions of uridine 5'-triphosphate (UTP) for use in promoting increased mucociliary clearance of retained mucous secretions of the human airways, middle/inner ears or sinuses are disclosed. Novel Formulation I comprises UTP and aqueous solution having a therapeutic concentration between 5 and 45 mg/mL, a controlled tonicity within the range of 250 to 100 mOsM, a pH between 7.0 and 7.5, and is sterile. The pH-adjusted composition is capable of long-term storage in the refrigerated state with a shelf life of up to 30 months. Formulation I may be delivered therapeutically either in a nebulized form or in a liquid form. Novel Formulation II comprises UTP in an aqueous solution or suspension having a therapeutic concentration approaching the limit of UTP's solubility at ambient temperature. This high concentration allows delivery of a therapeutic amount of UTP in very small volumes (50 to 100 .mu.L) suitable for administration via portable hand-held devices such as metered dose inhalers.Type: GrantFiled: December 23, 1997Date of Patent: October 19, 1999Assignee: Inspire Pharmaceuticals, Inc.Inventors: Karol K. LaCroix, Christy L. Shaffer, Karla M. Jacobus, Janet L. Rideout, David J. Drutz, Richard C. Evans, William Pendergast
-
Patent number: 4722891Abstract: Recombinant E. coli clones which cell surface-express Legionella pneumophila antigens, a method for utilizing these clones for the detection of Legionella antibodies in a clinical sample, and a method for isolation of mono-specific anti-Legionella antibodies are disclosed. The recombinant clones are produced by ligating fragmented Legionella DNA to pBR322 which is then used to transform the appropriate E. coli host. Clones that cell surface-express individual Legionella antigens are selected by screening cellularly intact clones using anti-Legionella antibodies to probe for cell surface expression. An enzyme-linked immunosorbant assay (ELISA) is disclosed which utilizes the Legionella antigen-expressing clones to detect anti-Legionella antibodies.Type: GrantFiled: June 20, 1984Date of Patent: February 2, 1988Assignee: Board of Regents, The University of Texas SystemInventors: David J. Drutz, Barry I. Eisenstein, N. Cary Engleberg